International Student Tuberculosis (TB) Testing

Temple University requires students from countries with a high incidence of tuberculosis (TB) to be screened for TB.  There are two types of TB testing, a blood test (IGRA, interferon gamma release assay) and a skin test (Mantoux skin test or PPD).  PPD results must be reported in millimeters induration.  Both tests are acceptable though the IGRA test is preferred in people who have received a TB vaccine (BCG) in childhood.  

A positive test result will not preclude you from registering or participating in classes.  If testing is positive, a chest x-ray will be required.  TB testing and x-rays must be completed within 6 months of starting classes at Temple.  We will accept test and chest x-ray results from a medical provider in your home country if they are printed in English.  Please upload these results through the Uploads tab of your Patient Health Portal (use the Immunization record or HSC and CPH Immunization, Titer And-Or Physical Record option). 

If you cannot get testing while at home, it can be done at Student Health Services (and needs to be completed in the first semester of enrollment).   We can bill your insurance, or you can pay the out-of-pocket student cost.  A list of these costs can be found at this https://studenthealth.temple.edu/appointments/prices 

If you have any questions after reviewing this information, or to schedule an appointment, please call 215-204-7500 and ask to speak with a nurse.  You can also email Student Health:  SHS@temple.edu 

To learn more about TB testing, please go to this website 

https://www.cdc.gov/tb/risk-factors/country.html 

Countries of High Incidence include:

Afghanistan Greenland Northern Mariana Islands Pakistan 
Algeria Guam Palau 
Angola Guatemala Panama 
Argentina Guinea Papua New Guinea 
Armenia Guinea-Bissau Paraguay 
Azerbaijan Guyana Peru 
Bangladesh Haiti Philippines 
Belize Honduras Qatar 
Benin India Romania 
Bhutan Indonesia Russian Federation 
Bolivia (Plurinational State of) Bosnia and Herzegovina Botswana Iraq Rwanda 
Brazil Kazakhstan Sao Tome and Principe 
Brunei Darussalam Kenya Senegal 
Burkina Faso Kiribati Sierra Leone 
Burundi Korea (Democratic People’s Republic of) Korea (Republic of) Singapore 
Cabo Verde Kyrgyzstan Solomon Islands 
Cambodia Lao People's Democratic Republic Latvia Somalia 
Cameroon Lesotho South Africa 
Central African Republic Chad Liberia South Sudan 
China Libya Sri Lanka 
China, Hong Kong SAR Lithuania Sudan 
China, Macao SAR Madagascar Suriname 
Colombia Malawi Syrian Arab Republic 
Comoros Malaysia Tajikistan 
Congo Maldives Tanzania (United Republic of) Thailand 
Congo (Democratic Republic of) Cote d'Ivoire Mali Timor-Leste 
Djibouti Marshall Islands Togo 
Dominican Republic Mauritania Trinidad and Tobago 
Ecuador Mexico Tunisia 
El Salvador Micronesia (Federated States of) Moldova (Republic of) Turkmenistan 
Equatorial Guinea Mongolia Tuvalu 
Eritrea Morocco Uganda 
Eswatini Mozambique Ukraine 
Ethiopia Myanmar Uruguay 
Fiji Namibia Uzbekistan 
French Polynesia Nauru Vanuatu 
Gabon Nepal Venezuela (Bolivarian Republic of) Viet Nam 
Gambia Nicaragua Yemen 
Georgia Niger Zambia 
Ghana Nigeria Zimbabwe 
 Niue  

* Taken from Appendix B: 2026 High-Incidence Country List: https://www.acha.org/wp-content/uploads/ACHA_TB-Risk-Assessment-and-Management-Guidelines_MAY-2026.pdf